Skip to main content
Premium Trial:

Request an Annual Quote

InDevr Inks $14.7M BARDA Contract to Develop FluChip Test

NEW YORK (GenomeWeb) – InDevr announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority to finish the development of a microarray-based test for influenza.

Should it complete project milestones, Boulder, Colo.-based InDevr could receive up to $14.7 million to see the array, called FluChip-8G, through to commercialization.

BARDA's support will "enable us to complete the final stages of product development and conduct clinical studies for a 510(k) submission" to the US Food and Drug Administration, said InDevr CEO Kathy Rowlen. "If all goes well, we will launch the first commercial version of FluChip-8G in 2016."

BARDA is part of the Office of the Assistant Secretary for Preparedness and Response within the US Department of Health and Human Services. Part of the office's mission is to support the development of new tests for influenza viruses.

FluChip-8G is capable of rapidly genotyping influenza viruses directly from clinical samples, according to the firm. Should it garner FDA clearance, the company said it will market the test to hospitals, urgent care facilities, and clinical laboratories, enabling physicians to "rapidly distinguish between seasonal strains and potential pandemic non-seasonal strains of the influenza virus, such as H5N1 or H7N9."

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.